FyMed Inc., a specialty pharmaceutical company focused on the development and commercialization of novel therapeutics announced that its application covering the Fy10 technology platform was allowed for issuance as a new patent by the USPTO. Read More...

Tags: patent, drug discovery, precision medicine, fy10, antineoplastic, anti-inflammatory

Researchers at FyMed, Inc., a pharmaceutical company with specialization in innovative evidence-based approaches in drug discovery, have identified novel antineoplastic benefits from FY103B, its new and proprietary lead candidate in the non-steroidal anti-inflammatory (NSAID) category. Read More...

Tags: NSAID, superior, less toxic, safety, ibuprofen, naproxen, aspirin, cancer, antineoplastic, efficacy